A Pilot Clinical Trial of Dendritic Cell Vaccine Loaded With Autologous Tumor for Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Bevacizumab; Daclizumab; Dendritic cell vaccines
- Indications Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- 11 Jun 2018 Biomarkers information updated
- 06 Aug 2012 Planned end date changed from 1 May 2012 to 1 May 2015 as reported by ClinicalTrials.gov.
- 17 May 2012 Additional lead trial investigator (Tanyi J) added as reported by ClinicalTrials.gov.